Optical coherence tomography

Optical coherence tomography (OCT) is a non-invasive, high-resolution imaging technique using low-coherence light interferometry to visualize tissue microstructures. In the context of enterprise risk management (ERM), OCT serves as a critical diagnostic tool for medical device validation. It must comply with international standards such as ISO 15201-1 for electromagnetic compatibility and IEC 60601-1 for general safety and essential performance. The technology enables the quantification of retinal pathologies, such as lamellar macular holes, which is essential for the risk-benefit analysis required by the EU MDR 2017/745 and Taiwan's Medical Device Act. For companies managing OCT-based products, the core risk-adjusted value lies in the precision of the imaging data, which directly impacts clinical decision-making and regulatory approval. Accurate OCT-based-definition of conditions like macular pseudoholes is vital for establishing the product's intended use and performance claims during the pre-market phase. This ensures the company avoids the risk of mislabeling or misrepresenting device capabilities to regulatory bodies like the FDA or TFDA.

OCT technology is applied in enterprise risk management through three key operational steps. First, Design Verification: Companies use OCT to validate that the imaging capabilities of their devices meet the technical specifications defined during the design process, as required by ISO 13485. Second, Clinical Risk Assessment: OCT-derived quantitative data (e.g., retinal thickness measurements) are used to perform risk-adjusted benefit-risk assessments, ensuring the device's clinical value outweighs its potential harms. Third, Post-Market Surveillance (PMS): Companies must systematically collect and analyze OCT-related performance data from the field to monitor long-term safety. For example, a company implementing OCT-based-monitoring of macular holes might be closely closely monitored by the FDA for device-related adverse events. Key Performance Indicators (KPIs) include: OCT image-to-reference-standard correlation (>0.90),--turnaround time for clinical data analysis (under 48 hours), and post-market adverse event rate (target <0.5%). This structured approach mitigates the risk of product recalls and legal liability. 積穗科研股份有限公司（Winners Consulting Services Co.）協助企業建立這些數據驅動的風險管理流程。

Taiwan enterprises face three primary challenges when implementing OCT technology. First, the Regulatory Challenge: The Taiwan FDA (TFDA)--based classification of OCT devices requires rigorous technical documentation, including optical safety and biocompatibility data. The solution is to establish a robust regulatory affairs (RA) function early in the product development lifecycle. Second, the Data--Privacy Challenge: OCT images constitute sensitive personal health information (PHI) under the Taiwan Personal Data Protection Act (PDPA) and the EU's GDPR. Companies must implement strict data--anonymization protocols and secure storage solutions. Third, the Technical-Challenge: OCT technology evolves rapidly, and maintaining a competitive edge requires continuous R&D investment. The strategic response involves partnering with academic institutions for R&D and investing in AI-enhanced OCT analysis capabilities. A typical implementation timeline includes a 6-month preparation phase for regulatory compliance, followed by a 12-month pilot phase for clinical validation. 積穗科研股份有限公司（Winners Consulting Services Co.）提供從法規分析到ISO 13485導入的完整支援。

Winners Consulting Services Co., Ltd. specializes in Optical coherence tomography-related regulatory and risk management topics for Taiwan enterprises, delivering compliant management systems within 90 days. Our team has assisted over 100 companies in navigating the complexities of medical device regulations, including ISO 13485, EU MDR, and Taiwan's Medical Device Act. We provide data-driven solutions that- -turn OCT technical capabilities into measurable risk-adjusted advantages.申請免費機制診斷：https://winners.com.tw/contact